Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIDE-A: Avelumab plus Intermittent Axitinib in mRCC
NCT04698213Phase 2Unknown
- Sponsor
- Consorzio Oncotech
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib, avelumab in metastatic renal cell carcinoma (mRCC), sponsored by Consorzio Oncotech. Status: unknown.
02
Drugs
axitinibavelumab
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT04698213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04698213.